Company: AZN
Filing Date: 2025-11-03
Form Type: 6-K
Source: 0001654954-25-012502
Chunk: 1

Company: ASTRAZENECA PLC
Filing Date: 2025-11-03
Form: 6-K
Chunk 1
---
            | 1,222,275,967 |           99.36 |     7,861,875 |            0.64 |       1,230,137,842 |                                           79.33 |      2,628,613 |

Michel Demaré, Chair AstraZeneca said: "Today's significant vote in favour of the Board's proposal demonstrates strong shareholder support for AstraZeneca's harmonised listing structure in London, Stockholm and New York. As the Company continues to expand and invest in our growing markets, our new structure will offer the flexibility to access the broadest available pool of capital, including in the US, enabling more shareholders to participate in AstraZeneca's exciting future."

#### Next steps and timetable
The expected timetable of principal events as set out in the Circular and Notice of GM remains unchanged and is replicated below. The following dates and times are indicative only and are subject to change. If any of the dates set out in the timetable change, the Company will give notice of this change by issuing an announcement through a Regulatory News Service.

| Expected date for termination of ADR Programme, delisting of        
 AstraZeneca ADSs and cancellation of the listing and trading of     
 AstraZeneca US Bonds on Nasdaq                                      | 2 February 2026                      |
| Expected time and date for commencement of trading in AstraZeneca   
 Shares and AstraZeneca US Bonds on the NYSE                         | By 8:00 a.m. (ET) on 2 February 2026 |
| Expected date for the issuance of AstraZeneca DIs to relevant CREST 
 participant accounts                                                | On or around 2 February 2026         |
| Expected date for the issuance of statements of entitlement for     
 existing CSN Eligible Certificated Shareholders and CSN             
 Participants                                                        | By no later than 16 February 2026    |

A copy of the special resolution passed at the GM has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

#### Issued capital
As at 30 October 2025, the number of issued shares of the Company was 1,550,712,906 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against the Resolution. In accordance with the Company's Articles of Association, on a poll